{"Clinical Trial ID": "NCT00091832", "Intervention": ["INTERVENTION 1:", "- Bisphosphonate IV Q4W", "In open bisphosphonate every 4 weeks (Q4W) by intravenous infusion", "INTERVENTION 2:", "Denosumab 30 mg Q4W", "Denosumab 30 mg by subcutaneous injection every 4 weeks (Q4W)"], "Eligibility": ["- Breast adenocarcinoma confirmed histologically or cytologically", "At least one bone metastasis"], "Results": ["Performance measures:", "Percentage change in baseline at week 13 in creatinine-adjusted urinary N-telopeptide (uNTx/Cr)", "- Rate of change of the reference value at week 13 in creatinine-corrected urinary N-telopeptide (uNTx/Cr) calculated using ((week 13 base value) / base value) x 100.", "Calendar: Baseline and Week 13", "Results 1:", "Title of arm/group: Bisphosphonate IV Q4W", "Description of the arm/group: Biphosphonate opened every 4 weeks (Q4W) by intravenous infusion", "Total number of participants analysed: 38", "Average (standard deviation)", "Unit of measure: Percentage change -10.19 (208.84)", "Results 2:", "Title of arm/group: Denosumab 30 mg Q4W", "Description of the arm/group: Denosumab 30 mg by subcutaneous injection every 4 weeks (Q4W)", "Total number of participants analysed: 40", "Average (standard deviation)", "Unit of measure: Percentage change -52.87 (95.14)"], "Adverse Events": ["Undesirable Events 1:", "Total: 15/43 (34.88 per cent)", "Anemia 0/43 (0.00 %)", "- Febrile spinal cord aplasia 0/43 (0.00 %)", "Febrile neutropenia 1/43 (2.33%)", "Leucopenia 0/43 (0.00 %)", "Neutropenia 1/43 (2.33%)", "Thrombocytopenia 0/43 (0.00 %)", "Angine pectoris 0/43 (0.00 %)", "- Cardiac tamponade 0/43 (0.00 %)", "Cardiorespiratory arrest 0/43 (0.00 %)", "Cardiopulmonary failure 1/43 (2.33%)", "Pericardial infusion 0/43 (0.00 %)", "Adverse Events 2:", "Total: 11/42 (26.19 per cent)", "Anemia 1/42 (2.38 per cent)", "1/42 (2.38%)", "- Febrile neutropenia 0/42 (0.00 %)", "- Leucopenia 0/42 (0.00 %)", "Neutropenia 0/42 (0.00 %)", "Thrombocytopenia 0/42 (0.00 %)", "Angine pectoris 1/42 (2.38%)", "- Cardiac Tapponade 0/42 (0.00 %)", "Cardiorespiratory arrest 0/42 (0.00 %)", "Cardiopulmonary failure 0/42 (0.00 %)", "1/42 (2.38%)"]}